rF1V-1018 Vaccine for Pneumonic Plague Prevention
This study is testing a vaccine called rF1V-1018 to see how well it works, how safe it is, and if people can tolerate it. The vaccine aims to prevent pneumonic plague, a serious illness. Researchers will give different doses and schedules of rF1V-1018 to healthy adults aged 18 to 55. They will measure the levels of antibodies (proteins that fight infection) in your blood and watch for any side effects. The goal is to find the best way to give the vaccine. This study plans to enroll 148 participants, but its current recruitment status is unclear.
- Study design
- This is an interventional study that will test six different ways of giving the rF1V-1018 vaccine in healthy adults. Up to two of the best ways will be chosen for further study.
- What's involved
- You would receive the vaccine and have blood drawn at different times. You would also have regular clinic visits for safety checks and evaluations.
- Compensation
- Not stated in the trial record.
- Follow-up
- You would be monitored for injection reactions for 7 days after each vaccine, for general side effects for 28 days after each vaccine, and for serious side effects for 6 months after your final vaccine.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age
At a glance
Conditions
NCT07207408
Where you'd take part
This study runs at 4 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
CTI Clinical Research Center
Cincinnati, Ohiostudy coordinator listed
Recruiting
103
Miami, Floridano site contact published
Active, not recruiting
AMR- El Dorado
El Dorado, Kansasno site contact published
Active, not recruiting
AMR- Las Vegas
Las Vegas, Nevadano site contact published
Active, not recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Anti-rF1V antibody level4 weeks after final study vaccine
- Evaluate safety of rF1V-1018injection reactions through 7 days after each study vaccine, adverse events for 28 days after each study vaccine; SAEs, MAEs, imAESIs through 6 months after the final study vaccine
Evaluate adverse events